Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases. / Nielsen, Valdemar Wendelboe; Yao, Yiqiu; Egeberg, Alexander; Thomsen, Simon Francis.
In: Drugs of the Future, Vol. 48, No. 3, 2023, p. 165-172.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Spesolimab. Anti-IL-36R monoclonal antibody Treatment of generalized pustular psoriasis Treatment of immune-mediated inflammatory diseases
AU - Nielsen, Valdemar Wendelboe
AU - Yao, Yiqiu
AU - Egeberg, Alexander
AU - Thomsen, Simon Francis
PY - 2023
Y1 - 2023
N2 - The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.
AB - The palette of biologic therapy is growing rapidly to improve the treatment and management of inflammatory immune-driven diseases. The interleukin-36 (IL-36) receptor has become a prom-ising target for therapeutic intervention, with early studies of anti-IL-36 receptor treatment demonstrating rapid inhibition of the IL-36 signaling pathway and improvement of disease symp-toms. Spesolimab, a humanized anti-IL-36 receptor monoclo-nal antibody, is one of the latest additions, showing promising results in the treatment of generalized pustular psoriasis and a possible effect in ulcerative colitis. In this review, we present the current literature on spesolimab, including pharmacodynam-ics, pharmacokinetics, efficacy and safety in the treatment of several immune-mediated inflammatory diseases.
KW - Spesolimab
KW - BI-655130
KW - MAB-92
KW - Generalized pustular psoriasis
KW - IL-36R
KW - Monoclonal antibody
U2 - 10.1358/dof.2023.48.3.3500035
DO - 10.1358/dof.2023.48.3.3500035
M3 - Journal article
VL - 48
SP - 165
EP - 172
JO - Drugs of the Future
JF - Drugs of the Future
SN - 0377-8282
IS - 3
ER -
ID: 340531009